Application of immune checkpoint inhibitors in the comprehensive treatment of advanced non-small cell lung cancer

doi:10.3760/cma.j.issn.1673-422X.2019.08.012

Abstract

Abstract: In recent years, immunotherapy has become an important part of the treatment for advanced non-small cell lung cancer (NSCLC). Tumor cells can escape from the body′s immune system by mediating various immune escape mechanisms, among which programmed death-1/programmed death ligand-1 (PD-1/PD-L1) mediated immune escape plays an important role. Currently, chemotherapy, radiotherapy and molecular targeted therapy have certain limitations in the treatment of advanced NSCLC. Recent studies have found that the combined application of PD-1/PD-L1 inhibitor and other treatment methods has certain synergistic effect, thus enhances the anti-tumor effect and further prolongs the survival of patients. Immunotherapy brings not only changes in the treatment patterns of NSCLC, but also challenges in the screening of target population and the management of treatment-related adverse reactions. Summarizing the research progress on immune checkpoint inhibitors in the comprehensive treatment of advanced NSCLC can provide reference for the best treatment of NSCLC.

Key words: Lung neoplasms, Immunotherapy, PD-1/PD-L1, Comprehensive therapy

Bai Xinya, Zhang jinmeng, Sun Yang, An Yongheng . Application of immune checkpoint inhibitors in the comprehensive treatment of advanced non-small cell lung cancer[J]. Journal of International Oncology, 2019, 46(8): 500-504.

References

［1］ Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492. ［2］ Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments［J］. Lancet, 2017, 389(10066): 299-311. DOI: 10.1016/S0140-6736(16)30958-8. ［3］ Borghaei H, Pazares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer［J］. N Engl J Med, 2015, 373(17): 1627-1639. DOI: 10.1056/NEJMoa1507643. ［4］ Reck M, Rodriguezabreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer［J］. N Engl J Med, 2016, 375(19): 1823-1833. DOI: 10.1056/NEJMoa1606774. ［5］ Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial［J］. Lancet, 2016, 387(10030): 1837-1846. DOI: 10.1016/S0140-6736(16)00587-0. ［6］ Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization［J］. Cell, 2018, 175(2): 313-326. DOI: 10.1016/j.cell.2018.09.035. ［7］ Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point［J］. Nature, 2017, 541(7637): 321-330. DOI: 10.1038/nature21349. ［8］ Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer［J］. J Clin Oncol, 2016, 34(25): 2969-2979. DOI: 10.1200/JCO.2016.66.9861. ［9］ PazAres L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer［J］. N Engl J Med, 2018, 379(21): 2040-2051. DOI: 10.1056/NEJMoa1810865. ［10］ Gandhi L, RodriguezAbreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer［J］. N Engl J Med, 2018, 378(22): 2078-2092. DOI: 10.1056/NEJMoa1801005. ［11］ Rivero L, Bunn B. Impower132 study shows atezolizumab in combinationwith carboplatin and pemetrexed reduced the risk of disease worsening or death (PFS) instage Ⅳ non squamous NSCLC［EB/OL］. ［2018-09-28］. http://www.ascopost.com/News/59093. ［12］ Sharabi AB, Lim M, Deweese TL, et al. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy［J］. Lancet Oncol, 2015, 16(13): e498-e509. DOI: 10.1016/S1470-2045(15)00007-8. ［13］ Gong J, Le TQ, Massarelli E, et al. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination［J］. J Immunother Cancer, 2018, 6(1): 46. DOI: 10.1186/s40425-018-0361-7. ［14］ Yuan Z, Fromm A, Ahmed KA, et al. Radiotherapy rescue of a nivolumab-refractory immune response in a patient with PD-L1-negative metastatic squamous cell carcinoma of the lung［J］. J Thorac Oncol, 2017, 12(9): e135-e136. DOI: 10.1016/j.jtho.2017.04.029. ［15］ Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial［J］. Lancet Oncol, 2017, 18(7): 895-903. DOI: 10.1016/S1470-2045(17)30380-7. ［16］ Kotecha R, Kim JM, Miller JA, et al. The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis［J］. Neuro Oncol, 2019, pii: noz046. DOI: 10.1093/neuonc/noz046. ［17］ Blake Z, Marks DK, Gartrell RD, et al. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition［J］. J Immunother Cancer, 2018, 6(1): 25. DOI: 10.1186/s40425-018-0338-6. ［18］ Schapira E, Hubbeling H, Yeap BY, et al. Improved overall survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases［J］. Int J Radiat Oncol Biol Phys, 2018, 101(3): 624-629. DOI: 10.1016/j.ijrobp.2018.02.175. ［19］ Bang A, Wilhite TJ, Pike LRG, et al. Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy［J］. Int J Radiat Oncol Biol Phys, 2017, 98(2): 344-351. DOI: 10.1016/j.ijrobp.2017.02.003. ［20］ Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study［J］. Lancet Oncol, 2017, 18(1): 31-41. DOI: 10.1016/S1470-2045(16)30624-6. ［21］ Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden［J］. N Engl J Med, 2018, 378(22): 2093-2104. DOI: 10.1056/NEJMoa1801946. ［22］ Ready N, Hellmann MD, Awad MM, et al. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes byprogrammed death ligand 1 and tumor mutational burden as biomarkers［J］. J Clin Oncol, 2019, 37(12): 992-1000. DOI: 10.1200/JCO.18.01042. ［23］ Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges［J］. Nat Rev Clin Oncol, 2018, 15(5): 325-340. DOI: 10.1038/nrclinonc.2018.29. ［24］ Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia［J］. Cancer Cell, 2014, 26(5): 605-622. DOI: 10.1016/j.ccell.2014.10.006. ［25］ Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC［J］. N Engl J Med, 2018, 378(24): 2288-2301. DOI: 10.1056/NEJMoa1716948. ［26］ Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)［J］. J Thorac Oncol, 2014, 9(2): 154-162. DOI: 10.1097/JTO.0000000000000033. ［27］ Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer［J］. N Engl J Med, 2017, 376(7): 629-640. DOI: 10.1056/NEJMoa1612674. ［28］ Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer［J］. JAMA Oncol, 2018, 4(8): 1112-1115. DOI: 10.1001/jamaoncol.2017.4526. ［29］ Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy［J］. Nat Rev Cancer, 2014, 14(3): 199-208. DOI: 10.1038/nrc3672. ［30］ Chang X, Lu X, Guo J, et al. Interventional therapy combined with immune checkpoint inhibitors: emerging opportunities for cancer treatment in the era of immunotherapy［J］. Cancer Treat Rev, 2019, 74: 49-60. DOI: 10.1016/j.ctrv.2018.08.006. ［31］ Backlund M, Freedman J. Microwave ablation and immune activation in the treatment of recurrent colorectal lung metastases: a case report［J］. Case Rep Oncol, 2017, 10(1): 383-387. DOI: 10.1159/000468982. ［32］ Guo Z, Meng C, Wei X, et al. Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: a case report［J］. Thorac Cancer, 2018, 9(5): 646-651. DOI: 10.1111/1759-7714.12600.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[6]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[7]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[8]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[9]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[10]	He Jiahui, Hu Qinyong. Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data [J]. Journal of International Oncology, 2024, 51(1): 29-36.
[11]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[12]	Guo Ciliang, Jiang Chunping, Wu Junhua. Gut microbiome and tumor immunotherapy [J]. Journal of International Oncology, 2023, 50(7): 432-436.
[13]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[14]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[15]	Gu Anqin, Long Jinhua, Jin Feng. Clinical research progress of immunotherapy for nasopharyngeal carcinoma [J]. Journal of International Oncology, 2023, 50(5): 299-303.